Previous 10 | Next 10 |
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million Realized Reimbursement on Higher ThyGeNEXT Pricing in Ja...
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by Thomas Burnell...
Gainers: Phoenix Tree (DNK) +91%.Naked Brand (NAKD) +64%.Kazia Therapeutics (KZIA) +32%.Micro Focus International (MFGP) +32%.BELLUS Health (BLU) +31%.InnSuites Hospitality Trust (IHT) +27%.FuelCell Energy (FCEL) +27%.Ashford Hospitality Trust (AHT) +24%.CIIG Merger (CIIC) ...
Interpace Biosciences (IDXG) -19.4% pre-market after disclosing it is is unable to file its Form 10-Q for the September quarter within the prescribed time period.Interpace says it is evaluating whether there has been an impairment of the carrying value of its Barrett intangible asset and whet...
Oncternal Therapeutics (ONCT) -26% after raising 'bought deal' offering to $22.5M.PaySign (PAYS) -25% on Q3 earnings release.Interpace Biosciences (IDXG) -17%.New Concept Energy (GBR) -12%.Alterity Therapeutics (ATHE) -11%.Yunhong CTI (CTIB) -8%.Lowe's Companies (LOW)-6%...
Nano cap Interpace Biosciences (IDXG) rallies 12% premarket on light volume in reaction to its announcement that results from a clinical validation study showed that ThyGeNEXT + ThyraMIR combination testing yielded the highest positive and negative predictive values versus other mar...
Study Demonstrates Superior Performance of ThyGeNEXT ® and ThyraMIR ® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the study entitled “Multipla...
Interpace Biosciences (IDXG): FQ2 GAAP EPS of -$1.35 misses by $0.32.Revenue of $5.45M (-13.1% Y/Y) misses by $3.06M.“We are pleased with our results year to date and for the quarter and our overall performance and progress toward our goals in spite of the challenges of the COVID-19 pa...
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year ; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products Pharma Services Business Produces Record Bookings of $9 million Audit Comm...
Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers:...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...